XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) Stock Price & Overview
NASDAQ:XOMAP • US98419J3059
Current stock price
The current stock price of XOMAP is 26.125 USD. Today XOMAP is down by -0.04%. In the past month the price increased by 0.15%. In the past year, price decreased by -0.1%.
XOMAP Key Statistics
- Market Cap
- 311.41M
- P/E
- 17.89
- Fwd P/E
- 53.36
- EPS (TTM)
- 1.46
- Dividend Yield
- 8.34%
XOMAP Stock Performance
XOMAP Stock Chart
XOMAP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to XOMAP. When comparing the yearly performance of all stocks, XOMAP is a bad performer in the overall market: 68.76% of all stocks are doing better.
XOMAP Fundamental Analysis
ChartMill assigns a fundamental rating of 6 / 10 to XOMAP. XOMAP has only an average score on both its financial health and profitability.
XOMAP Earnings
On March 18, 2026 XOMAP reported an EPS of 0.26 and a revenue of 13.76M. The company beat EPS expectations (264.45% surprise) and beat revenue expectations (22.07% surprise).
XOMAP Forecast & Estimates
11 analysts have analysed XOMAP and the average price target is 45.81 USD. This implies a price increase of 75.35% is expected in the next year compared to the current price of 26.125.
For the next year, analysts expect an EPS growth of -66.47% and a revenue growth 28.91% for XOMAP
XOMAP Groups
Sector & Classification
XOMAP Financial Highlights
Over the last trailing twelve months XOMAP reported a non-GAAP Earnings per Share(EPS) of 1.46. The EPS increased by 170.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 35.54% | ||
| ROA | 6.8% | ||
| ROE | 17.83% | ||
| Debt/Equity | 0.93 |
XOMAP Ownership
XOMAP Latest News, Press Relases and Analysis
XOMAP Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XOMAP
Company Profile
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Company Info
IPO: 1986-06-06
XOMA ROYALTY CORP - XOMA 8 5/8 PERP
2200 Powell Street, Suite 310
Emeryville CALIFORNIA US
Employees: 14
Phone: 15102047200
XOMA ROYALTY CORP - XOMA 8 5/8 PERP / XOMAP FAQ
What does XOMA ROYALTY CORP - XOMA 8 5/8 PERP do?
XOMA Royalty Corp. operates as a biotech royalty aggregator, which engages in helping biotech companies for enhancing human health. The company is headquartered in Emeryville, California and currently employs 13 full-time employees. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to funded partners. The firm has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The firm's commercial assets include OJEMDA (tovorafenib), IXINITY, XACIATO, VABYSMO (faricimab svoa), DSUVIA (sufentanil sublingual tablet), and MIPLYFFA (arimoclomol). Its Phase III assets include Rilvegostomig (AZD2936), Ficlatuzumab (AV-299), Ovaprene, D-Fi (FCX-007), Seralutinib, Cetrelimab (JNJ-63723283), Ersodetug (RZ358), and Mezagitamab (TAK-079). Its Phase II assets include Acimtamig (AFM13), AFM24, Vosaroxin, Aldoxorubicin, G03-52-01, PBF-680, PBF-677, Vidutolimod (CMP-001), and RZ-402. Its others assets include COM902 and MT-0169.
Can you provide the latest stock price for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
The current stock price of XOMAP is 26.125 USD. The price decreased by -0.04% in the last trading session.
Does XOMA ROYALTY CORP - XOMA 8 5/8 PERP pay dividends?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) has a dividend yield of 8.34%. The yearly dividend amount is currently 0.46.
What is the ChartMill technical and fundamental rating of XOMAP stock?
XOMAP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 6 out of 10.
Can you provide the upcoming dividend date for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
The next ex-dividend date for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is April 2, 2026.
What is the next earnings date for XOMAP stock?
XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) will report earnings on 2026-04-30.
What is the outstanding short interest for XOMA ROYALTY CORP - XOMA 8 5/8 PERP?
The outstanding short interest for XOMA ROYALTY CORP - XOMA 8 5/8 PERP (XOMAP) is 0.01% of its float.